Pear Therapeutics Acquires Two New Digital Therapeutic Technology Assets Addressing A Comprehensive Spectrum Of Depression Conditions

Pear Therapeutics, Inc. (Pear), which develops and markets prescription digital therapeutics (PDTs) acquired and/or licensed two new digital therapeutic technology assets intended to treat a spectrum of depression conditions. One was obtained from Waypoint Health Innovations, LLC, and the other was obtained from a researcher named Fredrik Holländare of Örebro University. Pear intends to leverage these two new assets to expand its depression product candidate PDT to treat mild, moderate, severe, and treatment-refractory depression.

Pear’s depression product candidate is being developed to be used alone or in combination with other treatments to help consumers with a . . .